1. Gitelman syndrome with a novel frameshift variant in SLC12A3 gene accompanied by chronic kidney disease and type 2 diabetes mellitus
- Author
-
Motoko Chiga, Masaki Hatanaka, Yosuke Imai, Takayasu Mori, Kenichiro Iio, Shinichi Uchida, Saki Bessho, Eisei Sohara, Haruhiko Kouhara, Jun-ya Kaimori, and Hiroki Omori
- Subjects
Male ,medicine.medical_specialty ,Hypokalemia ,Case Report ,Type 2 diabetes ,Hypocalciuria ,Frameshift mutation ,Internal medicine ,Medicine ,Humans ,Solute Carrier Family 12, Member 3 ,Renal Insufficiency, Chronic ,business.industry ,Type 2 Diabetes Mellitus ,General Medicine ,Gitelman syndrome ,Middle Aged ,medicine.disease ,Hyperaldosteronism ,Endocrinology ,Diabetes Mellitus, Type 2 ,Female ,medicine.symptom ,business ,Gitelman Syndrome ,Kidney disease - Abstract
Gitelman syndrome is an autosomal recessive genetic disease caused by pathogenic variants in SLC12A3 resulting in the loss of function of the Na–Cl co-transporter (NCC) in the distal tubules. Hypokalemia and diuretic effects can cause secondary type 2 diabetes and renal function decline. Here, we present the case of a 49-year-old male patient with chronic persistent treatment-resistant hypokalemia for the past 13 years who had been receiving treatment for type 2 diabetes mellitus for 6 years. He was referred to our department due to the presence of urinary protein, impaired renal function, high renin activity, and hyperaldosteronism. Laboratory test results showed hypokalemia, hypomagnesemia, hypocalciuria, and metabolic alkalosis. Using next-generation and Sanger sequencing, we identified a novel stop-gain variant (NM_000339.3:c.137del [p.His47fs]) and a missense variant (NM_000339.3:c.2927C > T [p.Ser976Phe]) in the SLC12A3 gene. This novel pathogenic variant was located at the intracellular N-terminus of the NCC. Based on these findings, the patient was diagnosed with Gitelman syndrome. The use of next-generation sequencing facilitated the exclusion of diseases with similar clinical symptoms.
- Published
- 2021